1. Wright J.M., Musini V.M. First-line drugs for hypertension. Cohrane Database Syst Rev 2009;(3):
2. CD001841.
3. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
4. Lindholm L.H., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553.
5. Bangalore S., Wild D., Parkar S. et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008;52:1062-1072.
6. Khan N., McAlister F .A. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737-1742.
7. Elliott W.J., Meyer P .M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta- analysis. Lancet 2007;369:201–207.
8. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.
9. Shorr R.I., Ray W.A., Daugherty J.R. Griffin M.R. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278(1):40-43.
10. Leonova M.V., Belousov Yu.B., Shteynberg L.L., Galitskiy A.A. Results farmakoepide-miologichesko- go study of hypertension PIFAGOR III (a survey of patients with hypertension). Sistemnye Gipertenzii 2010; (2): 33-39. Russian (Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Г алицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные Гипертензии 2010; 2: 33-39).
11. Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689.
12. Bühler F .R., Berglund G., Anderson O.K. et al. Double-blind comparison of the cardioselective beta- blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986;8 (Suppl 11):S122-127.
13. Czuriga I., Riecansky I., Bodnar J. et al. Cardioselective beta-blocker nebivolol with bisoprolol in hy- pertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular Drugs and Therapy 2003;17 (3): 257-263.
14. Hiltunen T.P ., Suonsyrjä T., Hannila-Handelberg T. et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007;20(3):311-318.
15. Frithz G. Influence on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001;4:229–230.
16. Haneda T., Ido A., Fujikane T., Tanaka H. et al. Effect of bisoprolol, a beta 1-selective beta-blocker , on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jap J Geriatrics 1998;35(1):33-38.
17. Vulpis V., Antonacci A., Prandi P . et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med 1991;82(4):189- 193.
18. Wang B., Song W., Liu G. The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus. Chin J Internal Med 2005;44:503-505.
19. Dominguez L.J., Barbagallo M., Jacober S.J. et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997;10(12 Pt 1):1349-1355.
20. Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol 1986;8 (Sup- pl 11):S96-99.
21. Mychka V.B., Sergienko V.B., Gornostaev V.V. et al. Effect of treatment with bisoprolol on cerebral perfusion in patients with metabolic syndrome. Arterial'naya Gipertenziya 2003; 9(5): 160-163. Russian (Мычка В.Б., Сергиенко В.Б., Г орностаев В.В. и др. Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом. Артериальная Гипертензия 2003; 9(5): 160-163).
22. Smith C., Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999;13(2):123-126.
23. Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis 1993;101(1):1-8.
24. Fogari R., Zoppi A., Pasotti C. et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(Suppl 7):S28-32.
25. Weiner L, Frithz G. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S106-112.
26. Frithz G., Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cho- lesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 11):S134-138.
